TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04025489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Randomized control trial of vitamin D supplementation
Description: This open-label randomized placebo-controlled prospective trial will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. Anthropometry, body composition, levels of vitamin D, blood glucose (including oral glucose tolerance test) and dietary assessments will be assessed periodically (every 3 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. Diet and exercise will be recommended as per the regular norms for overweight and obese subjects. Clinical and dietary profile, sunlight exposure, glycemic and lipid profile other metabolic parameters, body composition, hand grip strength, leukocyte telomerase length and telomerase activity will be assessed at enrolment time and one-year intervention. As mentioned above, genes related to ageing will be evaluated. Effects on polymorphisms of pro-ageing genes will be assessed.
Study: NCT02297100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A
Description: 100 units of botox spread out among 10 separate injections
Study: NCT01941394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells infusion
Study: NCT02007720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of CareTherapy
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of CareTherapy
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Study: NCT00082212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
Study: NCT04019145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EverX Posterior
Description: fiber reinforced bulk fill resin composite

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resins, Composite
Description: incremental packing of Nanohybrid Resin composite
Study: NCT01369459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIP Protocol
Description: We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
Study: NCT03510975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin melt form 120 μg
Description: desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal behavioral therapy
Description: Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Verbal behavioral therapy
Description: Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy with written check-list
Description: Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
Study: NCT02455505

Intervention type: BEHAVIORAL
Intervention: background questionnaire

Intervention type: BEHAVIORAL
Intervention: bereavement risk screening tool
Study: NCT03233815

Intervention type: DRUG
Intervention: Propofol
Description: Propofol anesthesia Dose: 4-6mg/kg/h

Intervention type: DRUG
Intervention: Sevoflurane
Description: Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
Study: NCT02090686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsatile Cupping
Description: 8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Cupping
Description: 8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
Study: NCT02546869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered SC using PFS, q4w up to Week 12.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Syringes
Study: NCT02574663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202 oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202 oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202 oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202 oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel + gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Folinic acid + Fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab
Description: IV Infusion
Study: NCT03654729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir (2 µmol/kg)
Description: Solution in 20 mL single dose glass vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calmangafodipir (5 µmol/kg)
Description: Solution in 20 mL single dose glass vials

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution in 20 mL single dose glass vials
Study: NCT03169478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: multiple myoma IUB dilatation group
Description: A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
Study: NCT00803712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
Study: NCT04074434

Intervention type: DEVICE
Intervention: Study Watch
Description: Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
Study: NCT02259205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriched Yogurt
Description: 150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain Yogurt
Description: 150 g plain yogurt will be provided daily for 8 weeks
Study: NCT03565874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback
Description: Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
Study: NCT03417752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to firearm safety PSA
Description: Exposed to firearm safety PSA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to firearm safety PSA
Description: Exposed to firearm safety PSA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to health promotion PSA
Description: Exposed to general health promotion PSA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to health promotion PSA
Description: Exposed to general health promotion PSA
Study: NCT00874159

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study: NCT04512144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace Smartphone Application
Description: Headspace is a smartphone application used for mindfulness, meditation, and stress reduction. It has been utilized in other behavioral and quality of life studies.
Study: NCT02806856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS neuroConn
Description: Cathodal on M1

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham
Study: NCT03701542

Intervention type: DIAGNOSTIC_TEST
Intervention: Microperymetry
Description: Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.

Intervention type: DIAGNOSTIC_TEST
Intervention: M-charts
Description: The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
Study: NCT03180203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTELLiVENT-ASV
Description: After ICU admission:~* The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~* After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if \>10minutes PEEP:\<9cmH2O,FiO2:\<41%,VT/IBW\<5ml/kg and RSB:\<106l/l\*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate \>35b/min or increases \>100% since start of SBT, FiO2 \>50%, PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional modes
Description: After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if \>10min PS\<11cmH2O,PEEP\<9cmH2O,FiO2\<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate \>35b/min or increases \>100% since the start of SBT, saturation \<92% or the PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT.
Study: NCT01952418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitor size
Description: Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor.
Study: NCT00762762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/copolymer/fluoride
Description: Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
Study: NCT02761590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training protocol
Description: The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circuit training protocol
Description: The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
Study: NCT01562717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times a day
Study: NCT04423133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Family Literacy Program
Description: Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
Study: NCT00535431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AER 001
Description: 60 mg (in nebuliser), twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sterile saline nebulised, twice daily for 28 days
Study: NCT03170817

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Perfusion Rest/Stress Digital PET/CT
Description: Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~1. One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of \~20 minute duration.~2. A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~3. One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of \~20 minute duration~Total patient time will take approximately up to 120 minutes.

Intervention type: DRUG
Intervention: N-13 ammonia
Description: 5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress

Intervention type: DRUG
Intervention: Regadenoson
Description: 0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
Study: NCT01766531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: body bioelectrical impedance
Study: NCT01672268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac computed tomography
Description: cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac computed tomography
Description: cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
Study: NCT02752438

Intervention type: DEVICE
Intervention: HFOV
Description: HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.

Intervention type: DEVICE
Intervention: HFOV
Description: HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
Study: NCT00941200

Intervention type: BIOLOGICAL
Intervention: Blood collection
Study: NCT02210520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsatile ultrasound
Description: 1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsatile ultrasound
Description: 1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous ultrasound
Description: 1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous ultrasound
Description: 1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: 1 W/cm², 2 minutes in 6 points around the back spine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Description: 1 W/cm², 2 minutes in 6 points around the back spine
Study: NCT04849663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: free fat graft
Description: fat harvested from patient will be used to cover exposed root

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subepithelial graft
Description: subepitheial graft harvested from palate
Study: NCT02562586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Suction Drainage System
Description: patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
Study: NCT03832829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect composite restoration
Description: Restoration of tooth with extensive substance loss
Study: NCT02762435

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: light touch at established points on hand and wrist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no contact with the subject

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: moderate pressure at established points on hand and wrist
Study: NCT01845597

Intervention type: PROCEDURE
Intervention: MAKOplasty® medial UKA
Description: A robot guided medial Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
Study: NCT01060423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Starting dose of 400mg/m2, followed by weekly 250mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Starting dose of 400mg/m2, followed by weekly 250mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² to be administered every two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irinotecan eluting BEADS
Description: A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
Study: NCT04306497

Intervention type: DRUG
Intervention: TCM prescriptions
Description: TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.

Intervention type: DRUG
Intervention: TCM prescriptions
Description: TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
Study: NCT03060226

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: Search of blood predictive marker (s)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: Search of blood predictive marker (s)
Study: NCT03836157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: The dose will not be recalculated unless the patient has ±10% weight change.
Study: NCT02297100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinumtoxin A
Description: 100 units of botox spread out among 10 separate injections
Study: NCT03836157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
Study: NCT03639857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532nm laser
Description: 532nm laser will be used to treat the lesion in this study arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1064nm laser
Description: 1064nm laser will be used to treat the lesion in this study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: The topical corticosteroid will be used to treat the lesion in this study arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: The topical corticosteroid will be used to treat the lesion in this study arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid
Description: The topical corticosteroid will be used to treat the lesion in this study arm.
Study: NCT02981199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cell transplantation
Description: conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cell transplantation
Description: conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion
Study: NCT03245320

Intervention type: DEVICE
Intervention: Integra TITAN™ Total Shoulder Generation 1.0
Description: Total Shoulder Arthroplasty or Hemiarthroplasty